search
The increasing focus on targeted therapies has driven significant growth in HPAPI manufacturing. These compounds are designed to be highly active at very low doses, making them powerful therapeutic tools in areas like oncology, but also introducing substantial complexity in handling and production.
May 21, 2026
Developing effective oral solid dosage products remains a cornerstone of pharmaceutical innovation. From tablets to capsules, solid oral dosage forms remain the most widely used delivery format due to their stability, convenience, and patient compliance.
May 14, 2026
The evolution of targeted therapies has positioned antibody-drug conjugates (ADCs) among the most promising modalities in modern oncology. By combining the targeting precision of biologics with the cell-killing power of cytotoxic drugs, ADCs offer a more focused approach to cancer treatment.
May 12, 2026
In pharmaceutical development, confidence in data is everything. Whether supporting early-stage research or regulatory submissions, analytical methods must consistently deliver accurate and reproducible results. That's where method validation parameters come into play.
May 06, 2026
Antibody-drug conjugates (ADCs) have rapidly become a cornerstone of modern oncology, driven by significant advances in payload-linker technologies. While early ADC programs struggled with stability and manufacturing complexity, recent innovation has drastically improved their clinical viability.
Apr 02, 2026
